ESTRO 2020 Abstract Book

S57 ESTRO 2020

OC-0113 Dosimetric and NTCP comparison of photon treatment techniques in lung cancer D. Hattu 1 , J. Van Loon 1 , S. Peeters 1 , D. Emans 1 , S. Nijsten 1 , W. Van Elmpt 1 , D. De Ruysscher 1 1 Maastricht Radiation Oncology MAASTRO clinic, Radiotherapy, Maastricht, The Netherlands Purpose or Objective Plan quality is generally evaluated and compared based on dosimetric values. Normal tissue complication probability (NTCP) models that predict the probability of side effects can assist in evaluating which dosimetric improvements are of clinical relevance. In The Netherlands NTCP models are used to select patients for proton therapy: the model- based approach (Langendijk et al. 2013). The aim of this planning study is to quantify the difference between commonly used photon treatment techniques based on dosimetric values and NTCP values calculated according to the models used for proton therapy selection. Material and Methods 26 NSCLC patients were planned with 3 commonly used photon treatment techniques: a 5 field sliding window IMRT technique, a VMAT technique (2 half arc beams) and a hybrid technique (2 opposing APPA fields complemented with 1 or 2 VMAT beams). Treatment plans were made with Eclipse (v15.5 Varian Medical Systems, Palo Alto) by experienced RTTs and met the dosimetric requirements of the clinical guidelines for target coverage and OARs (De Ruysscher et al. 2017). The prescribed dose to the PTV was 60 Gy in 30 fractions. Treatment plans were evaluated for PTV coverage and OARs based on dosimetric and NTCP values. NTCPs were calculated according to 3 validated NTCP models used for proton therapy selection: mortality (Defraene et al. 2019), grade 2 pneumonitis (Appelt et al. 2014) and grade 2 dysphagia (Wijsman et al. 2015). Analogous to selecting patients for proton therapy, the cut-off in ∆NTCP to determine the optimal photon technique was ≥2% for grade ≥3 toxicity and ≥10% for grade 2 toxicity. Results All 78 plans met the V95%≥95% requirement for the primary tumor and involved node coverage. Median dose, volume and NTCP values for the hybrid, VMAT and IMRT technique are depicted in Table 1 for the MHD, MLD, V5 of the lungs and the MED. The lowest MHD was achieved with the VMAT technique. Both MLD and MED were not affected by a particular technique, whereas the V5 of the lungs was lowest using a hybrid technique. Based on NTCPs, the risk of 2-year mortality was lowest with VMAT. For grade 2 pneumonitis and dysphagia, the median differences in NTCP were ≤1%. Looking at individual patient differences, the ∆NTCP for mortality was ≥2% in 13/26 and 11/26 patients, mostly favoring VMAT (11/13) or IMRT (8/11) over the hybrid technique. The ∆NTCP for grade 2 pneumonitis did not exceed the 10% threshold. For grade 2 dysphagia only 1 patient met the 10% cut-off in favor of the hybrid DVH parameters and associated NTCP values according to the model-based approach allow objective selection of optimal photon techniques for lung cancer patients. Based on DVH parameters, there is a trade-off between the V5 of the lungs (hybrid) and the MHD (VMAT). According to model-based selection, VMAT is favored for most patients, predominantly due to ≥2% decreased probability of mortality. These results depend on the selected models, and these models should therefore be validated and updated on a regular basis. technique. Conclusion

Poster Highlights: Poster highlights 3 CL : Prostate

PH-0114 Dose-volume effects for GI toxicity following EBRT for prostate cancer in the FLAME trial V. Groen 1 , P. Zuithoff 2 , M. Van Schie 3 , E. Monninkhof 2 , M. Kunze-Busch 4 , H. De Boer 1 , J. Van der Voort van Zijp 1 , F. Pos 3 , R.J. Smeenk 4 , K. Haustermans 5 , S. Isebaert 5 , T. Depuydt 5 , H.M. Verkooijen 2 , U.A. Van der Heide 3 , L. Kerkmeijer 1 1 UMC Utrecht, Radiation Oncology, Utrecht, The Netherlands ; 2 UMC Utrecht, Epidemiology, Utrecht, The Netherlands ; 3 The Netherlands Cancer Institute, Radiation Oncology, Amsterdam, The Netherlands ; 4 Radboud University Nijmegen Medical Centre, Radiation Oncology, Nijmegen, The Netherlands ; 5 University Hospitals, Radiation Oncology, Leuven, Belgium Purpose or Objective The phase 3 multicenter randomized controlled FLAME trial (NCT01168479) compared effectiveness and toxicity of external beam radiotherapy (EBRT) with and without a simultaneous integrated boost up to 95Gy to the macroscopic tumor in intermediate and high risk prostate cancer patients. Earlier, we showed that cumulative toxicity rates up to two years were comparable for the standard and dose-escalated arm. The aim of the present study was to investigate the association between radiation dose to the rectum and gastro-intestinal (GI) toxicity (≥ grade 2) in the FLAME study cohort. Material and Methods All 571 patients with intermediate and high risk prostate cancer of the FLAME trial were included in this study. The dose-volume effect of the absolute and relative rectal dose volume histogram (DVH) parameters (D2cc and D50%) in relation to the cumulative GI toxicity ≥ grade 2 during the first 4 years of follow-up was assessed. A mixed model analysis for repeated measurements was used, including the total study cohort irrespective of randomization. We performed both crude analyses and analyses adjusted for age, cardiovascular disease (CVD), diabetes mellitus (DM), T-stage, baseline toxicity ≥ grade 1, institute and hormonal therapy. We calculated cumulative incidences for overall GI toxicity ≥ grade 2 and toxicity per GI subdomain. Finally, we assessed the crude association between D2cc and D50% on the GI toxicity endpoints rectal pain, proctitis, fecal incontinence, diarrhea and rectal bleeding. Adjusted odds ratios (OR) for the subdomains